Design and Development of Transdermal Patches for Trandolapril
Trandolapril is an antihypertensive agent which undergoes extensive first pass metabolism making it a possible candidate for transdermal delivery. Patches were prepared using hydroxypropylmethylcellulose, eudragit RL 100, gantrez and carbopol. The results of FTIR and DSC revealed no interaction between drug and polymers. The loss of moisture and uptake of moisture were within the limits. The formulations showed an extended release of the drug upto period of 24 hours during in vitro permeation studies and showed non Fickian drug release. Stability of the optimized formulation was investigated as per ICH guidelines and was found to be stable with respect to drug content and in vitro permeation.
Chien YW, Transdermal therapeutic systems, In: Robinson JR, Vincent HL, editors. Controlled drug delivery fundamentals and applications. 2nd ed., New York: Marcel Dekker, Inc. 1987: 523-552.
Misra AN, Transdermal drug delivery. In: Jain NK, editors. Controlled and novel drug delivery. New Delhi: India: CBS Publisher and distributor. 1997: 100-129.
Sankar V, Johnson DB, Sivanan V, Ravichandran V, Raghuraman SR, Design and evaluation of nifedipine transdermal patches, Indian J Pharm Sci. 2003; 65: 510-515.
Sadhana PG, Jain SK, Effective and controlled transdermal delivery of metaprolol tartrate, Indian J Pharm Sci. 2005; 67: 346-350.
Saleh A, Al-suwayeh, Effect of penetration enhancers on the transdermal delivery of isradipine through excised rabbit skin, Saudi Pharmaceutical Journal. 2008; 16:155-160.
Guay DR. Trandolapil: A Newer Angiotensin- Converting Enzyme Inhibitor. Clin Ther. 2003; 25: 713-775.
Wiseman LR, McTavish D. Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994; 48: 71-90.
Klaus Florey, Analytical profiles of drug substances and excipients, Academic press, Sandiego, USA, 2000: 643-647.
Amnuaikit C, Ikeuchi .I, Ogawara K, Higaki K and Kimura T, skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use, Int J Pharm. 2005; 289:167-178.
Verma PRP and Iyer SS, Transdermal delivery of propranolol using mixed grades of Eudragit: deign and in vitro and in vivo evaluation, Drug Dev Ind Pharm. 2000; 26: 471-476.
Devi VK, SaishivamS, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride, Drug Dev Ind Pharm. 2003; 29: 495-503.
Jamkhandi VG, Mulla JS, Vinay BL, Shivakumar HN, Formulation, characterization and evaluation of matrix –type transdermal patches of a model antihypertensive drug, Asian Journal of Pharmaceutics. 2009; 1: 59-63.
Saxena M, Mutalik S, Reddy MS, Formulation and evaluation of transdermal patches of metaclopromide hydrochloride, Indian Drugs. 2006; 43: 740-745.
Anna Gumieniczek, Hanna Hopkala. High Performance liquid chromatographic assay of Trandolapril in capsules. Acta Polo Pharm. 2000; 57: 253-255.
Gupta JRD, Irchhiaya R, Garud N, Priyanka T, Prashanth D, Patel JR, Formulation and evaluation of matrix type transdermal patches of glibenclamide, International Journal of Pharmaceutical Sciences and Drug Research. 2009; 1: 46-50.
Ligang Zhao, Liang Fang, Yongnan Xu, Transdermal delivery of penetrants with differing lipophilicities using O – acylmenthol derivatives as penetration enhancers, European Journal of Pharmaceutics and Biopharmaceutics. 2008; 69: 199-213.
Shojaei AH, Zhou SL, Li X. Transbuccal Delivery of Acyclovir (II): Feasibility, System Design, and In Vitro Permeation Studies, J Pharm Pharmaceut Sci. 1998; 1: 66-73.
Saranjit Singh. Drug stability testing and shelf-life determination according to international guidelines, Pharmaceutical technology. 1999; 23: 68-74.